File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Transdermal fentanyl for severe cancer-related pain

TitleTransdermal fentanyl for severe cancer-related pain
Authors
KeywordsNeoplasms
Fentanyl
Administration, cutaneous
Palliative care
Pain
Issue Date1997
Citation
Palliative Medicine, 1997, v. 11, n. 3, p. 233-239 How to Cite?
AbstractA prospective phase II study was conducted to define the analgesic efficacy, acceptability and toxicity of the transdermal therapeutic system (TTS) of fentanyl in Chinese patients with severe cancer-related pain. A total of 14 patients was treated with TTS fentanyl at doses ranging from 25 to 100 μg h-1; initial doses were chosen according to their previous opioid requirement. Standard supportive therapy was given as required. A brief pain inventory (using a 10-point scale) was used to assess patients at days 0, 7 and 14. Pain control on day 14 with TTS fentanyl was successful in six patients, with a reduction in the common side-effects of other opioids and improvement in general well-being. Seven patients did not complete the 14-day trial: two developed dizziness and nausea within 3 h of application; and in five, TTS fentanyl was insufficiently flexible to control increasing pain during the first week. TTS fentanyl was effective and well tolerated in 43% of patients. Acute dizziness and nausea within the first few hours after application and the relative inflexibility of dose-adjustment both limited the use of TTS fentanyl.
Persistent Identifierhttp://hdl.handle.net/10722/280458
ISSN
2020 Impact Factor: 4.762
2015 SCImago Journal Rankings: 1.914
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYeo, Winnie-
dc.contributor.authorLam, Kwok K.-
dc.contributor.authorChan, Anthony T.C.-
dc.contributor.authorLeung, Thomas W.T.-
dc.contributor.authorNip, Sau Y.Wu-
dc.contributor.authorJohnson, Philip J.-
dc.date.accessioned2020-02-17T14:34:05Z-
dc.date.available2020-02-17T14:34:05Z-
dc.date.issued1997-
dc.identifier.citationPalliative Medicine, 1997, v. 11, n. 3, p. 233-239-
dc.identifier.issn0269-2163-
dc.identifier.urihttp://hdl.handle.net/10722/280458-
dc.description.abstractA prospective phase II study was conducted to define the analgesic efficacy, acceptability and toxicity of the transdermal therapeutic system (TTS) of fentanyl in Chinese patients with severe cancer-related pain. A total of 14 patients was treated with TTS fentanyl at doses ranging from 25 to 100 μg h-1; initial doses were chosen according to their previous opioid requirement. Standard supportive therapy was given as required. A brief pain inventory (using a 10-point scale) was used to assess patients at days 0, 7 and 14. Pain control on day 14 with TTS fentanyl was successful in six patients, with a reduction in the common side-effects of other opioids and improvement in general well-being. Seven patients did not complete the 14-day trial: two developed dizziness and nausea within 3 h of application; and in five, TTS fentanyl was insufficiently flexible to control increasing pain during the first week. TTS fentanyl was effective and well tolerated in 43% of patients. Acute dizziness and nausea within the first few hours after application and the relative inflexibility of dose-adjustment both limited the use of TTS fentanyl.-
dc.languageeng-
dc.relation.ispartofPalliative Medicine-
dc.subjectNeoplasms-
dc.subjectFentanyl-
dc.subjectAdministration, cutaneous-
dc.subjectPalliative care-
dc.subjectPain-
dc.titleTransdermal fentanyl for severe cancer-related pain-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1177/026921639701100308-
dc.identifier.pmid9205657-
dc.identifier.scopuseid_2-s2.0-0030983399-
dc.identifier.volume11-
dc.identifier.issue3-
dc.identifier.spage233-
dc.identifier.epage239-
dc.identifier.isiWOS:A1997XD19800008-
dc.identifier.issnl0269-2163-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats